InvestSMART

Lumos Diagnostics Holdings Limited (ASX:LDX)

ALERT: Price-sensitive ASX Announcement for LDX
Current share price for LDX : $0.115 -0.01 (-8%)+
Announcement
Release
18 May 2026 9:49AM
Price at Release
$0.125
Full Release
download
Summary
Lumos Diagnostics Holdings Limited announced significant progress in the U.S. rollout and reimbursement of its FebriDx® rapid diagnostic test. With the recent FDA CLIA waiver, FebriDx® is now widely available across various healthcare settings, reaching 80 million patients annually. The company has achieved strong initial reimbursement results, with over 90% of claims paid and average payments exceeding the Medicare rate. FebriDx® is being used routinely in 44 WellStreet urgent care clinics, and Lumos continues to expand its pilot sites and sales pipeline in the urgent care market, laying the groundwork for the upcoming flu season.
Key Points
  • FebriDx® U.S. rollout has shown promising initial reimbursement results with over 90% of claims paid.
  • Payments are averaging above the Medicare fee schedule rate of US$41.38 per test.
  • FebriDx® is now in routine use across 44 WellStreet urgent care clinics.
  • Lumos Diagnostics is expanding its pilot sites with new urgent care operators and chains.
  • FebriDx® received FDA CLIA waiver, expanding its use to over 300,000 locations.
  • The waiver allows broader deployment, potentially reaching 80 million patients per annum.
  • Lumos is actively working on building its sales pipeline in the urgent care market.
  • Early commercialization efforts are foundational for the 2027/28 U.S. flu season.
  • Lumos provides reimbursement education and claims optimization for customers.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.